Macrophage Exosomes Disarm Immune Cells and Fuel Ovarian Cancer Spread

A study published in the Journal of Ovarian Research has uncovered a previously underappreciated mechanism by which ovarian cancer turns the body’s own immune defenses into bystanders, allowing tumor cells to seed the peritoneal cavity largely unopposed. The research, led by Jun Ma, Junyan Zhu, and Jieru Zhou of Renji Hospital, Shanghai Jiaotong University School of Medicine, together with colleagues at Ningbo Hangzhou Bay Hospital, focuses on tumor-associated macrophages, the most abundant immune cells in the peritoneal microenvironment of ovarian cancer. According to the findings, these macrophages release small membrane-bound vesicles called exosomes that carry programmed death-ligand 1, or PD-L1, on their surface. Once absorbed by CD8-positive T cells, the principal killer cells of the adaptive immune system, these vesicles set off a chain of metabolic events that cripples the cells’ ability to destroy tumors, contributing directly to peritoneal metastasis in epithelial ovarian cancer.

Exosomes are tiny extracellular vesicles, typically measuring between 30 and 150 nanometers, that cells use to shuttle proteins, lipids, and genetic material to one another. In the tumor microenvironment, they have emerged as important messengers of intercellular communication, and in the case of tumor-associated macrophages, they appear to function as vehicles of immune suppression. The Shanghai-led team wanted to understand precisely how these vesicles metabolically reprogram CD8-positive T cells. Metabolic reprogramming has become a central theme in tumor immunology because it is now clear that the functional state of an immune cell is inseparable from the fuel it burns and the way its mitochondria operate. An exhausted T cell is not merely a cell that has received too many inhibitory signals; it is a cell whose internal power plants have been fundamentally altered.

To model the peritoneal environment of ovarian cancer in the laboratory, the researchers induced M2-type macrophages from the mouse macrophage cell line RAW264.7 by exposing them to the cytokines interleukin-4 and interleukin-13. M2 macrophages are the immunosuppressive, wound-healing variety that tumors preferentially recruit, in contrast to the inflammatory M1 type that helps marshal anti-tumor responses. From these cells the team isolated exosomes using a commercial exosome isolation kit, and then co-cultured the resulting vesicles, which they called TAMs-Exo, with CD8-positive T cells harvested from mouse spleens. They found that these exosomes carry high levels of PD-L1 and are efficiently taken up by the T cells. Once inside, the vesicles significantly impaired three critical dimensions of T-cell function: cytotoxicity, the capacity to kill target cells; proliferation, the ability to expand in numbers after encountering a tumor; and the secretion of effector molecules, including the inflammatory messenger interferon-gamma and the cell-killing enzyme granzyme B.

The mechanistic heart of the paper lies in what happened to the T cells’ mitochondria after exposure to TAMs-Exo. The researchers systematically assessed mitochondrial function using a battery of assays: Western blotting to track protein expression, JC-1 staining to measure mitochondrial membrane potential, ATP assays to quantify cellular energy charge, and assays for reactive oxygen species and lipid peroxidation to gauge oxidative damage. They also directly measured the rate of fatty acid oxidation, the metabolic pathway by which cells break down fatty acids in mitochondria to generate energy. What they observed was a paradoxical combination. On one hand, the exosomes activated the PGC-1α/PPARα/CPT1A axis, a transcriptional program that upregulates the machinery of fatty acid oxidation. On the other hand, the cells showed a collapse in mitochondrial membrane potential, depletion of ATP, and accumulation of reactive oxygen species and lipid peroxides, which are hallmarks of mitochondrial dysfunction.

PGC-1α, or peroxisome proliferator-activated receptor gamma coactivator 1-alpha, is a master regulator of mitochondrial biogenesis and oxidative metabolism. It works in concert with PPARα, a nuclear receptor that controls the expression of genes involved in fatty acid catabolism, including CPT1A, the rate-limiting enzyme that shuttles fatty acids into mitochondria for oxidation. In a healthy context, this axis helps cells adapt to energy demands by tuning oxidative capacity. But the new findings suggest that when this axis is pathologically overactivated in CD8-positive T cells, the result is not enhanced fitness but a kind of metabolic overload. The cells are driven to burn fatty acids at an abnormally high rate even as their mitochondria lose the membrane potential needed to sustain efficient oxidative phosphorylation, leaving them energy-starved and drowning in oxidative byproducts. The researchers interpret this as a compensatory response that ultimately deepens the damage rather than repairing it.

To establish that PD-L1 carried on the exosomes is the causal agent rather than a mere passenger, the team performed two complementary experiments. First, they stimulated CD8-positive T cells with recombinant PD-L1 protein and found that it mimicked the effects of the macrophage-derived exosomes, reproducing the activation of the PGC-1α/PPARα axis, the shift toward excessive fatty acid oxidation, and the resulting mitochondrial dysfunction. Second, they used short hairpin RNA to knock down PD-L1 expression in the macrophages before isolating exosomes, and found that exosomes depleted of PD-L1 lost much of their ability to induce T-cell dysfunction. In a further test of the metabolic mechanism, treatment with etomoxir, a pharmacological inhibitor of fatty acid oxidation, significantly reversed the T-cell impairment caused by the exosomes. Together, these results argue that exosomal PD-L1 is not simply an inhibitory checkpoint molecule delivered from the outside but a trigger that rewrites the metabolic identity of the recipient T cell from within.

Importantly, the team extended their findings beyond the culture dish. They established an ID8 intraperitoneal metastasis mouse model, a widely used system in which murine ovarian cancer cells are introduced into the peritoneal cavity to recapitulate the pattern of spread seen in human epithelial ovarian cancer. In this model, administration of TAMs-Exo promoted the formation of ascites, the fluid accumulation characteristic of advanced ovarian cancer, and increased the number of peritoneal metastatic nodules. When the researchers examined the CD8-positive T cells recovered from the peritoneal cavity of these mice, they found the same molecular signatures observed in vitro: abnormal activation of the PGC-1α/PPARα axis and evidence of mitochondrial dysfunction. This convergence between the cell culture data and the in vivo observations strengthens the case that the exosome-mediated metabolic reprogramming is not an artifact of laboratory conditions but a process that operates in living tissue.

The clinical significance of these findings is considerable. Ovarian cancer is among the most lethal gynecologic malignancies, and its propensity to spread across the peritoneal lining rather than through the bloodstream makes peritoneal metastasis the dominant pattern of disease progression. Immune checkpoint inhibitors, which have transformed the treatment of many cancers by releasing PD-1/PD-L1-mediated brakes on T cells, have shown limited benefit in ovarian cancer, and the reasons have remained incompletely understood. This study suggests one contributing mechanism: even if a patient’s T cells are liberated from inhibitory signaling at their own PD-1 receptors, they may remain metabolically crippled by exosomes shed from tumor-associated macrophages. In other words, the checkpoint problem may be only the visible surface of a deeper metabolic problem that standard immunotherapy does not address.

The authors propose that targeting what they describe as a metabolic checkpoint may offer a new combination strategy for overcoming immunotherapy resistance in ovarian cancer. In practice, this could mean blocking exosomal PD-L1 to prevent the vesicles from reprogramming T cells in the first place, or inhibiting excessive fatty acid oxidation flux with agents such as etomoxir-like compounds to relieve the mitochondrial strain imposed on the killer cells. The research was supported by the National Natural Science Foundation of China under grant number 81974440, and all animal experiments were approved by the Renji Hospital Animal Experiment Ethics Committee of Shanghai Jiaotong University School of Medicine. Much work remains before such strategies can be translated to patients, including the development of clinically viable approaches to intercept macrophage-derived exosomes and the validation of these mechanisms in human tumor samples. Nevertheless, by tracing a direct line from macrophage vesicles through a defined transcriptional axis to mitochondrial collapse and tumor spread, the study adds a compelling new layer to the growing recognition that the battle against cancer is fought as much in the metabolism of immune cells as in their receptors.

Subject of Research: How exosomal PD-L1 from tumor-associated macrophages metabolically reprograms CD8-positive T cells to promote peritoneal metastasis in epithelial ovarian cancer

Article Title: TAMs-derived exosomal PD-L1 drives mitochondrial dysfunction and aberrant fatty acid oxidation via PGC-1α/PPARα axis to promote peritoneal metastasis in epithelial ovarian cancer

Article References: Ma, J., Wang, Q., Cen, Q., Zhu, J., & Zhou, J. (2026). TAMs-derived exosomal PD-L1 drives mitochondrial dysfunction and aberrant fatty acid oxidation via PGC-1α/PPARα axis to promote peritoneal metastasis in epithelial ovarian cancer. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02277-6

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02277-6

Keywords: ovarian cancer, tumor-associated macrophages, exosomes, PD-L1, CD8 T cells, mitochondrial dysfunction, fatty acid oxidation, PGC-1α, PPARα, metabolic reprogramming, peritoneal metastasis, tumor microenvironment